Maria Grazia di Iasio
Overview
Explore the profile of Maria Grazia di Iasio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Secchiero P, Voltan R, di Iasio M, Melloni E, Tiribelli M, Zauli G
Clin Cancer Res
. 2022 Jul;
28(13):2973.
PMID: 35775195
No abstract available.
2.
Secchiero P, Rimondi E, di Iasio M, Agnoletto C, Melloni E, Volpi I, et al.
Clin Cancer Res
. 2013 Mar;
19(8):1949-59.
PMID: 23468057
Purpose: To investigate the potential link between C-reactive protein (CRP), a known biomarker of acute and chronic inflammation, and TRAIL, a cytokine which plays a key role in the immune-surveillance...
3.
di Iasio M, Zauli G
Invest New Drugs
. 2012 Oct;
31(2):458-60.
PMID: 23054209
The effect of Nutlin-3, a small molecule inhibitor of the MDM2/p53 interaction, was investigated on the steady-state mRNA levels of the transcription factors E2F1 and E2F7 in a cohort of...
4.
Tisato V, Zauli G, Voltan R, Gianesini S, di Iasio M, Volpi I, et al.
PLoS One
. 2012 Jun;
7(6):e39543.
PMID: 22737245
Background: The inflammatory properties of vein endothelium in relation to chronic venous disease (CVD) have been poorly investigated. Therefore, new insights on the characteristics of large vein endothelium would increase...
5.
Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, et al.
Haematologica
. 2012 Jun;
97(11):1722-30.
PMID: 22689683
Background: Both the multi-kinase inhibitor sorafenib and the small molecule inhibitor of the MDM2/p53 interaction, nutlin-3, used alone, have shown promising anti-leukemic activity in acute myeloid leukemia cells. Thus, in...
6.
di Iasio M, Norcio A, Melloni E, Zauli G
Invest New Drugs
. 2012 Jan;
30(6):2403-6.
PMID: 22238073
The basal SOCS1 mRNA levels were significantly lower in p53(mutated) BJAB and MAVER leukemic cell lines with respect to p53(wild-type) SKW6.4 and JVM-2 leukemic cell lines, p53(wild-type) primary B chronic...
7.
Voltan R, di Iasio M, Bosco R, Valeri N, Pekarski Y, Tiribelli M, et al.
Clin Cancer Res
. 2011 Jul;
17(17):5649-55.
PMID: 21753157
Purpose: The oncogene TCL1 plays a key role in the development of B chronic lymphocytic leukemia (B-CLL), but it is not known whether TCL1 could be modulated by therapeutic approaches....
8.
Secchiero P, Rimondi E, di Iasio M, Voltan R, Gonelli A, Zauli G
J Cell Physiol
. 2011 Jul;
227(5):1829-37.
PMID: 21732354
A range of cell types of mesenchymal origin express α-smooth muscle actin (α-SMA), a protein that plays a key role in controlling cell motility and differentiation along the fibrocyte and...
9.
Corallini F, Celeghini C, Rimondi E, di Iasio M, Gonelli A, Secchiero P, et al.
J Cell Physiol
. 2011 Jun;
226(9):2279-86.
PMID: 21660951
The soluble member of the TNF-R superfamily osteoprotegerin (OPG) is abundantly released under basal conditions by both mesenchymal stem cells (MSC) and fibroblasts and by endothelial cells upon stimulation with...
10.
di Iasio M, Addobbati R, Radillo O, Voltan R
Invest New Drugs
. 2011 Jun;
30(4):1761-5.
PMID: 21626114
No abstract available.